Changes in Hong Kong stocks | Cansino Biotech (06185) is now up more than 35%, the agency indicates that the company's development route and antigen design are roughly similar to Moderna

According to the news, Cansino Biotech (06185) rose more than 60% in early trading and narrowed in the afternoon. As of press release, it had risen 35.82% to HK$31.7, with a turnover of HK$1,368 billion.

According to the news, on August 19, Moderna and MSD announced that the phase III clinical trial of their jointly developed melanoma mRNA cancer vaccine had reached the main end, becoming the world's first clinically proven mRNA therapeutic cancer vaccine, confirming the viability and commercialization value of mRNA technology for cancer treatment.

Lyon released a research report saying that since Moderna is conducting clinical research on the same platform for lung cancer, kidney cancer, and bladder cancer, this success is a platform-level valuation reassessment. Cansino Biologics is positioned on the same technical path. Currently, its rhabdomyosarcoma program is in the investigator-initiated clinical trial (IIT) stage, and the glioma project is still awaiting pre-clinical approval. The Group's development route and antigen design are roughly similar to Moderna. The main difference is its three-component lipid nanoparticle (LNP) system, which is safer than traditional formulations and may support a stronger cellular immune response.